Contract Biomanufacturing Services Global Market - Forecast to 2025

www.MarketResearchReports.com
Category : Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

Introduction to Report
 Launch Date: August 17, 2017
 Number of Pages: 206
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 3,600
Price For Site User License: USD 5,400
Price For Global User License: USD 7,200
Delivery Time: Within 24 Hours (During Working
Days)

About the Report
The contract biomanufacturing global market is
expected to grow at double digit CAGR to reach
$36.6 billion by 2025.
Biomanufacturing is a widely used term to
describe manufacture of biologic molecules for
various stages of drug development right from
pre-clinical stage to commercial supply. The
biologic drug manufacturing is a complex process
involving huge capital and sound technical
expertise.

Key Highlights:
Many large and small pharmaceutical companies are
turning to outsourcing the drug manufacture process to
reduce capital investments on capacities and focus
more on their core competencies.
Contract manufacturing organizations, particularly for
R&D and clinical trials, are making product
manufacture, more efficient and often less costly.
This option is more viable for smaller and low-funded
companies for their in-house candidate product
manufacturing needs, whereby, the companies can
avoid $50-$150 million facility costs for construction of
fixed, dedicated stainless steel bioreactor-based
bioprocessing systems and outsource their
manufacturing requirements to CMOs which use single-
use facilities which typically cost $25-$40 million for
commercial manufacture.

Key Highlights: Continues..
ere is a continued growth of biopharmaceutical market
which is expected to nearly double in next 10 years.
This will be a result of continued new product
approvals, expansion of indications for current
products which include less-developed countries
becoming more affluent and increased drug demand of
the aging population in the U.S. and other major
pharmaceutical markets.
Aging populations are at a high risk of developing
chronic diseases such as cancer and arthritis and these
diseases are being precisely targeted using
biopharmaceuticals.
Many blockbuster drugs losing their exclusivity are
also giving room for many biosimilar (and bio-betters)
companies to enter into the world’s biopharmaceuticals
market subsequently attracting many CROs, CDMOs,
and CMOs to enter into the picture.

Now-a-days CMOs are gaining much prominence due
to increased demand for the clinical and commercial
supply of biologics.
Such prominence is achieved mainly through capacity
expansions or more easily through mergers and
acquisitions.
In September 2016, Asahi Glass, a Japanese
manufacturer of glass, chemicals, and high-tech
materials acquired a leading European bio-CMO,
Biomeva Holding GmbH to expand their life science
business and expand into newer geographies.
Contract manufacturing services are mainly benefitting
the small scale companies which lack the facilities for
the biomanufacturing and also intend to not invest in
fixed assets like steel bioreactors and bioprocessing
facilities thus giving opportunity for the CMOs to gain
market presence.

The global bio-manufacturing outsourcing market is
driven by factors such as globalization of bio-
manufacturing facilities, increased funding from private
venture capitals and government organizations,
increasing outsourcing budgets and emergence of
latest technologies such as single-use bioreactors.
Increased funding has been seen as a boon for
Chinese CMOs for becoming a lucrative market for
biomanufacturing outsourcing.
An example of such funding includes Autek Bio who
raised an impressive $100 million for building Asia’s
largest CMO facility in south Beijing from private and
government sources.
There are restraints and threats as well which could
potentially hamper the biomanufacturing outsourcing
market.

Report Coverage:
1. Contract Biomanufacturing Global Market
2. Executive Summary
3. Contract Biomanufacturing Services
4. Company Profiles
For more details regarding Report coverage see the last slide

Company Coverage: (Partial List)
1. Abzena Plc
2. Albany Molecular Research, Inc
3. Asahi Glass Co. Ltd.
4. Boehringer Ingelheim
5. Catalent Inc
6. Charles River Laboratories
7. Fujifilm Diosynth Biotechnologies
8. Horizon Discovery Group, Plc
9. Innovent Biologics
10. Jhl Biotech Inc.
11. Lonza Group
12. Merck Kgaa
13. Patheon N.V.
For more details regarding Report coverage see the last slide

Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
For regular industry updates subscribe to our newsletter
at:
http://www.marketresearchreports.com/subscribe-to-
newsletter

How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/UbZ
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Mr. Sudeep Chakravarty
Email : info@marketresearchreports.com
Phone: +1-302-703-9904 (USA) +91-8762746600 (India)

Contract Biomanufacturing Services Global Market - Forecast to 2025

Recommended

Recommended

More Related Content

More from Market Research Reports, Inc.

More from Market Research Reports, Inc. (20)

Recently uploaded

Recently uploaded (20)

Contract Biomanufacturing Services Global Market - Forecast to 2025